comparemela.com

Latest Breaking News On - Bruce beutler - Page 7 : comparemela.com

Short Interest in aTyr Pharma, Inc. (NASDAQ:LIFE) Increases By 69.4%

aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 408,200 shares, an increase of 69.4% from the March 15th total of 240,900 shares. Based on an average daily volume of 302,800 shares, the days-to-cover ratio is […]

Canada
San-diego
California
United-states
Roth-mkm
Paul-schimmel
Vr-adviser
Alyeska-investment-group
Royal-bank
Nasdaq
Atyr-pharma-inc
Vanguard-group-inc

Piper Sandler Increases aTyr Pharma (NASDAQ:LIFE) Price Target to $13.00

aTyr Pharma (NASDAQ:LIFE – Get Rating) had its price target hoisted by Piper Sandler from $9.00 to $13.00 in a research report sent to investors on Tuesday, The Fly reports. The firm currently has an overweight rating on the biotechnology company’s stock. A number of other equities analysts also recently issued reports on the company. […]

Canada
San-diego
California
United-states
Paul-schimmel
Roth-mkm
Piper-sandler
Royal-bank
Tower-research-capital
Millennium-management
Tyr-pharma-company-profile
Virtu-financial

aTyr Pharma (NASDAQ:LIFE) Price Target Raised to $13.00

aTyr Pharma (NASDAQ:LIFE – Get Rating) had its price objective increased by Piper Sandler from $9.00 to $13.00 in a report released on Tuesday, The Fly reports. They currently have an overweight rating on the biotechnology company’s stock. A number of other analysts have also recently commented on the stock. Royal Bank of Canada reiterated […]

San-diego
California
United-states
Canada
Roth-mkm
Paul-schimmel
Piper-sandler
Atyr-pharma-inc
Virtu-financial
Tower-research-capital
Millennium-management
Tyr-pharma-company-profile

aTyr Pharma, Inc. (NASDAQ:LIFE) Given Average Recommendation of "Moderate Buy" by Analysts

aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) has been given an average recommendation of “Moderate Buy” by the six brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price objective among […]

Canada
San-diego
California
United-states
Paul-schimmel
Roth-mkm
Atyr-pharma-inc
Royal-bank
Tower-research-capital
Millennium-management
Virtu-financial
Nasdaq

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.